bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version ecor capital llc san francisco ca   cortera company profile cortera business directory create account login developers search cortera for a business state alabama alaska arizona arkansas california colorado connecticut delaware district of columbia florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania puerto rico rhode island south carolina south dakota tennessee texas utah vermont virginia washington west virginia wisconsin wyoming home business directory holding and other investment offices ecor capital llc cortera support  ecor capital llc  illinois st san francisco  ca      view map   wwwecorcapcom looking for more information sign up for free company overview ecor capital llc is in the investors nec industry in san francisco ca this company currently has approximately  to  employees company details location type single location industry investors nec ownership private year founded  employees  to  have fresher information  update latest company news read all company news in the complete company credit report recent company alerts credit risk increase no overall payments no peer payments no public records no financial news no alerts on more than  companies today including mitchell industrial contractors inc montgomery marine repair walbro southern cleaning service inc ideal construction co coats electric co inc barnes  noble university of alaska fairbanks hammer  co ram enterprises inc community payment ratings latest community reviews of this company cortera is much more than an awesome business directory its an active community where real business people share the real deal on real businesses its invaluable intel thats now available for free get the inside scoop with ratings and reviews on ecor capital llc rate ecor capital llc on their payment behavior ask your network about ecor capital llc with cortera circles join the cortera community for free today the information contained in this company profile is compiled from third party sources including but not limited to public records user submissions and other commercially available data sources these sources may not be accurate complete or uptodate cortera makes no representations or warranties regarding and assumes no responsibility for the accuracy completeness or currency of the information contained herein cortera products are enabled by sofie™ our proprietary technology platform for rapid data processing robust analytics and flexible data access   cortera inc all rights reserved sitemap cortera support   how does it work  who do we help  company profiles  community  media  about todays hot company profiles volatus maximus llc voltaire vuden inc volume reversal survey volunteers of america inc w  b trucking inc vogt james b md vora shailesh c md voorhees arizona taste inc vogue more todays hot companies » recently updated companies l  l machine tool cross county bancshares inc powerhouse industrial supply inc contorno inc spires phillip construction goody  shoes advent i llc western sun shuttle inc jl loper construction air conditioning sec more recently updated companies » recently rated company profiles panalpina inc global merchandising inc stinger welding inc sunstar heating  aire ideal true value inc md thomas construction llc azuradisc jr ball contracting group inc slt express way inc law offices of susan m schauf more recently rated companies » industry directory terms  conditions privacy policy     ecor capital llc  current holdings  fintelio ecor capital llc current holdings from f d investorecor capital llc portfolio value  current positions ecor capital llc has disclosed  total holdings in their latest sec filings most recent portfolio value is calculated to be   usd actual assets under management aum is this value plus cash which is not disclosed ecor capital llc s top holdings are assembly biosciences inc nasdaqasmb  ironwood pharmaceuticals inc nasdaqirwd  galapagos nv nasdaqglpg  gilead sciences inc nasdaqgild  and ascendis pharma as nasdaqasnd  ecor capital llc s new positions include gilead sciences inc nasdaqgild  theravance biopharma inc nasdaqtbph  chemocentryx inc nasdaqccxi  cascadian therapeutics inc nasdaqcasc  and cascadian therapeutics inc nasdaqcasc  ecor capital llc s top industries are construction special trade contractors sic   building materials hardware garden supply and mobile home dealers sic   and measuring analyzing and controlling instruments photographic medical and optical goods watches and clocks sic   overview sec filings dg predictive value performance f industry all ecor capital llc holdings are listed in the following table this data is sourced from dg and f filings green rows indicate new positions red rows indicate closed positions add this fundto your dashboard this is a list of d and g filings made since the last quarterly f report if any file dateformsecurity prevshares currentshares changepercent prev valuex current valuex changepercent ‑‑ sc g rgls  regulus therapeutics inc   ‑‑ sc g fgen  fibrogen inc   this f was filed on  reporting periodformsecurity imputedshare priceprev sharescurrent shareschange percent prev value kcurrent value kchangepercent ‑‑ fhra agn  allergan plc call       ‑‑ fhra fgen  fibrogen inc         ‑‑ fhra alxn  alexion pharmaceuticals inc        ‑‑ fhra kura  kura oncology inc         ‑‑ fhra asnd  ascendis pharma as       ‑‑ fhra casc  cascadian therapeutics inc call     ‑‑ fhra gild  gilead sciences inc call     ‑‑ fhra tbph  theravance biopharma inc     ‑‑ fhra glpg  galapagos nv         ‑‑ fhra fwp  forward pharma as       ‑‑ fhra fate  fate therapeutics inc       ‑‑ fhra kin  kindred biosciences inc         ‑‑ fhra jnce  jounce therapeutics inc         ‑‑ fhra wve  wave life sciences ltd         ‑‑ fhra nbrv  nabriva therapeutics ag       ‑‑ fhra casc  cascadian therapeutics inc         ‑‑ fhra advm  adverum biotechnologies inc         ‑‑ fhra bmymp  bristolmyers squibb co         ‑‑ fhra sndx  syndax pharmaceuticals inc         ‑‑ fhra casc  cascadian therapeutics inc call    ‑‑ fhra irwd  ironwood pharmaceuticals inc       ‑‑ fhra orex  orexigen therapeutics inc       ‑‑ fhra agio  agios pharmaceuticals inc       ‑‑ fhra vsar  versartis inc         ‑‑ fhra atra  atara biotherapeutics inc         ‑‑ fhra syrs  syros pharmaceuticals inc         ‑‑ fhra acrs  aclaris therapeutics inc         ‑‑ fhra ctmx  cytomx therapeutics inc         ‑‑ fhra asmb  assembly biosciences inc       ‑‑ fhra ovas  ovascience inc       ‑‑ fhra vivmf  viveve medical inc         ‑‑ fhra drna  dicerna pharmaceuticals inc         ‑‑ fhra life  atyr pharma inc         ‑‑ fhra xncr  xencor inc         ‑‑ fhra rgls  regulus therapeutics inc         ‑‑ fhra edit  editas medicine inc        ‑‑ fhra derm  dermira inc        ‑‑ fhra cytk  cytokinetics inc       ‑‑ fhra ardx  ardelyx inc        ‑‑ fhra eglt  egalet corporation        ‑‑ fhra chemocentryx inc  l       ‑‑ fhra cmrx  chimerix inc        ‑‑ fhra fast  fastenal co        ‑‑ fhra bpmx  biopharmx corporation        ‑‑ fhra fprx  five prime therapeutics inc        ‑‑ fhra ccxi  chemocentryx inc     fintel ir  find the right investors for your company instantly fintel ir combines the comprehensive fintel ownership database with machine learning to provide advanced tools to make investor outreach fast and easy learn more now from the blog how to launch a hedge fund the piotroski score microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft investors  ecor ecor why ecor why choose ecor ecor capital fund lp is forging a new path in the art of investing in science a leading fundamental longshort equity hedge fund ecor capital fund specializes in finding rewarding opportunities others may not see and identifying compelling longterm investments in the biotech sector with a vigilant focus on the business case and a discerning eye for the highest quality science ecor capital llc the fund’s general partner conducts a detailed assessment of the financial and scientific viability of each investment before it is selected all investments are evaluated based on their intrinsic value their ability to meet real market needs their financial stability and their management team and talent base like the ecor restriction enzyme which helped to transform biomedical research the ecor hedge fund seeks to help move medical research forward through its investments while delivering superior returns for its investors with acceptable downside risk our approach our approach it is easy for an investor to be distracted by trends and the “wow factor” in the biotech industry instead of exhaustively assessing the financial and scientific fundamentals of a company that will make a good longterm investment ecor believes that investing in biotech is an art that requires fluency in both business and science as well as sophisticasted translational skills to connect the two worlds ecor has a unique approach to identifying assets and avoiding liabilities based on our knowledge of what ingredients make a rewarding longterm biotech investment this includes focus on relationships we nurture longterm relationships which gives us insight into a company’s scientific merit and expertise this often translates into a privileged position during pivotal investment moments an eye for potential we are happiest when we find rewarding opportunities others have not seen or recognize risk in an opportunity that others perceive as a certainty deep due diligence we start with a deep assessment of financial scientific viability and evaluate each potential company on intrinsic value market needs financial stability and talent of each of our companies worldclass experience ecor works with an extensive network of scientists and analysts to review all aspects of a potential investment our team also provides coaching to create companies that are capable of realizing their full potential copyright ecor capital  all right reserved member login username or email address password dont have an account with ecor create account ecor  the art of investing in science ecor why ecor what sets ecor apart bleeding edge science is our comfort zone ecor capital llc is a fundamental biotechnologyfocused investment advisory firm based in san francisco ecor evaluates and selects extraordinary biotechnology companies that are pursuing the highest quality science and demonstrate strong business fundamentals like the ecor restriction enzyme which helped to transform the biomedical field ecor seeks to help move medical research forward through investments into compelling biotech companies that are developing promising new solutions for untreated diseases contact the ecor team    partnership we nurture lasting relationships potential we expand the possibilities of science progress we are committed to innovation   ecor is committed to helping passionate drug hunters change the world about us forging a new path advancements in biotech are happening at a breakneck pace and ecor has the drive and vision to help patients with the most innovative science     investing in progress ecor seeks to move medical research forward through thoughtful investments that are evaluated for scientific merit and business case   a passion for patients advancements in the biotech industry affect the lives of many ecor is committed to playing a role in finding answers for unmet medical needs   looking for the exceptional ecor identifies gutsy companies that have committed management and the potential to create value over and over again we believe people are the most important factors in any investment opportunity leadership committed to success the ecor team shepherds great drugs and great people over the peaks and valleys of drug discovery and development learn more about our leadership team   oleg nodelman founder and managing director oleg nodelman is the founder and managing director of ecor capital llc a biotechfocused investment advisory firm with  years of experience in investing and consulting mr nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities before founding ecor mr nodelman was a portfolio manager at bvf partners one of biotech’s first dedicated hedge funds during his  years with bvf mr nodelman’s responsibilities spanned the entire investment process from opportunity generation and due diligence to portfolio management and trading mr nodelman began his career in strategic consulting and organizational management at mercer management consulting now oliver wyman where he worked with senior management from companies in a variety of industries to develop and implement longterm strategy and build shareholder value mr nodelman has a bachelor of science in foreign service with a concentration in science and technology from georgetown university sarah marriott chief operating officer and chief compliance officer ms marriott is the chief operating officer and chief compliance officer for ecor capital llc where she is responsible for regulatory and compliance issues ms marriott has experience working across the diverse areas of civil and criminal litigation most recently ms marriott served as a deputy district attorney in solano county california where she tried approximately  cases to a jury and  cases to the bench prior to serving as a prosecutor ms marriott practiced at orrick herrington  sutcliffe llp in san francisco for six years while there ms marriott handled breachofcontract disputes business tort claims public pensions employment and appellate advocacy as well as whitecollar criminal defense ms marriott previously completed a clerkship on the federal court of appeals for the tenth circuit ms marriott holds a law degree from the university of california berkeley and a bachelor of arts degree from amherst college joseph sum director of research joseph sum has spent the past eight years hunting for promising investments that may lead to solutions for devastating diseases as the director of research at ecor capital llc mr sum identifies and assesses opportunities to fund talented management teams in pursuit of novel therapeutic drugs and technologies he was previously a biotech specialist at a b asset management firm and worked as an analyst for bvf partners where he led the successful spin off of ziarco pharma from pfizer mr sum serves on the board of the new yorkbased breast cancer task force which provides early cancer detection and treatment services to patients without health insurance and has served on the boards of ziarco pharma and airmid inc he has bachelor of science degrees in chemical engineering and materials engineering from the university of california berkeley and is a cfa charterholder caroline stout analyst caroline stout specializes in operational and scientific analysis at ecor capital llc in her role as an ecor analyst ms stout informs the fund’s investment decisions by assessing clinical data and corporate insights to gain broad insights into biotechnology companies markets and emerging science she previously worked as an investment banking analyst at credit suisse in new york performing due diligence and financial valuation analysis for healthcare companies she has experience working on a range of transactions in the healthcare and biotechnology sectors including multibillion dollar leveraged buyouts initial public offerings and followon equity raises ms stout graduated magna cum laude from georgetown university with a bachelor of arts in economics a premedical concentration and cognitive science minor scott platshon analyst mr platshon joined ecor capital llc in october  after spending a year at aquilo partners a boutique life sciences investment bank alongside ms stout mr platshon serves as an analyst and is responsible for due diligence and analysis of biotechnology companies for valueoriented investment opportunities  at aquilo mr platshon prepared valuation materials and performed due diligence on ma licensing and private placement transactions in the biotech pharmaceutical and tools  diagnostics sector mr platshon holds a bachelor of science in bioengineering from stanford university and was advised by karl deisseroth the inventor of optogenetics and clarity two breakthrough neuroscience technologies catherine mcwilliams director of partner relations ms mcwilliams joined ecor capital llc to oversee the firm’s partner relations ms mcwilliams assumed this role in may  after spending six and a half years as a managing director of capital introductions at btig llc a privately owned boutique broker dealer at btig her responsibilities included building and maintaining institutional investor relationships in the south midwest and western us regions prior to btig ms mcwilliams spent two and a half years with ubs’s prime brokerage division in the dallas branch she began her career as a real estate investment analyst focused on student housing assets on collegiate campuses ms mcwilliams received her bba in finance from the mccombs business school at the university of texas – austin ecor helps move medical research forward through investments in compelling biotech companies portfolio our venture portfolio anagin anagin develops therapies that target mechanisms which result in neuropsychiatric diseases through abnormal neuroplasticity inflammation excitotoxicity and neurodegeneration visit site  atara biotherapeutics atara biotherapeutics nasdaq atra is developing new treatment options that may change the course of disease progression for patients with debilitating diseases such as cancer kidney diseases and other illnesses visit site  atyr pharma atyr pharma nasdaq life focuses on innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology a newly discovered set of physiological modulators visit site  avidity nanomedicines avidity nanomedicines draws on features of antibodydrug conjugates and nucleic acidbased medicines to create a transformative approach to the treatment of cancer and other serious diseases visit site  clementia clementia is a biopharmaceutical company focused on developing a treatment for fibrodysplasia ossificans progressiva fop visit site  collegium pharmaceutical collegium nasdaq coll is developing next generation abusedeterrent products for the treatment of chronic pain and other diseases visit site  denali therapeutics denali therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development visit site  editas medicine editas medicines mission is to translate its genome editing technology to enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases visit site  flex pharma flex pharma nasdaq flks is creating novel treatments for neuromuscular disorders and has demonstrated initial human efficacy related to muscle cramping visit site  intellia therapeutics intellia therapeutics core mission is to develop curative medicines by utilizing the promise of the crisprcas gene editing technology visit site  kezar life sciences kezar life sciences is a company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders visit site  kindred biosciences kindred biosciences nasdaq kin develops therapeutics for dogs cats and horses based on compounds and targets that have already demonstrated safety and efficacy in humans visit site  kura oncology kura oncology is committed to realizing the promise of precision medicines for cancer visit site  metacrine metacrine is a company targeting metabolic disease through advances in endocrine research visit site  nabriva nabriva therapeutics nasdaq nbrv is a biotech company focused on developing a new class of antibiotics pleuromutilins for the treatment of patients with serious infections caused by multidrug resistant pathogens visit site  naurex naurex is a clinical stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system visit site  oric pharmaceuticals oric pharmaceuticals is dedicated to discovering and developing novel therapies for treatmentresistant cancers visit site  sage therapeutics sage therapeutics nasdaq sage is developing and commercializing novel medicines to treat lifethreatening rare cns disorders visit site  scholar rock scholar rock is discovering and developing a new class of biologic therapies niche modulators that selectively target dysregulated growth factors in the disease microenvironment visit site  syndax pharmaceuticals syndax pharmaceuticals is a latestage biopharmaceutical company leveraging recent scientific insights on entinostat in the emerging field of immunooncology visit site  contact email infoecorcapcom phone  address ecor capital llc  illinois street san francisco ca  copyright ecor capital  all right reserved member login username or email address password dont have an account with ecor create account ecor capital llc institutional portfolio  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  ownership  insider trades  institutional portfolio ecor capital llc  illinois street san francisco california    report date  position statistics total positions  new positions  increased positions  decreased positions  positions with activity  sold out positions  total mkt value in  millions  institutional holdings information is filed by major institutions on form f with the securities and exchange commission sector weighting energy basic materials industrials consumer cyclicals consumer noncyclicals financials healthcare  technology telecommunication services utilities total positions new increased decreased activity sold out  positions as of  company class value of shares s ▼ change in value s change  shares held assembly biosciences inc com  new  ironwood pharmaceuticals inc com cl a     galapagos nv spon adr     ascendis pharma a s sponsored adr     kura oncology inc com  new  aclaris therapeutics inc com     cascadian therapeutics inc com new   new  cytomx therapeutics inc com   new  atyr pharma inc com     fate therapeutics inc com  new  atara biotherapeutics inc com     xencor inc com     ovascience inc com   new  kindred biosciences inc com     jounce therapeutics inc com   new  nabriva therapeutics plc shs  new  adverum biotechnologies inc com  new  versartis inc com   new  regulus therapeutics inc com   new  viveve med inc com new   new   first previousnext last  latest news headlines gatx corporation announces quarterly dividend am et   globenewswire rockwell collins shares jump as results beat forecast am et   reuters air france  klm  availability of the  first half financial report am et   globenewswire us stockswall st dragged lower by amazon tobacco stocks am et   reuters analysisgoogle facebook show power of ad duopoly as rivals stumble am et   reuters view all latest headlines closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex